WallStreetZenWallStreetZen

NASDAQ: AKBA
Akebia Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AKBA

Based on 2 analysts offering 12 month price targets for Akebia Therapeutics Inc.
Min Forecast
$1.25+84.64%
Avg Forecast
$1.63+140.03%
Max Forecast
$2.00+195.42%

Should I buy or sell AKBA stock?

Based on 3 analysts offering ratings for Akebia Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AKBA stock forecasts and price targets.

AKBA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 8%
93
HoldReiterates$1.25+84.64%2023-03-10
Needham
Bottom 8%
8
HoldDowngradesN/AN/A2022-03-31
Mizuho
Top 17%
84
HoldDowngrades$2.00+195.42%2022-03-31
Anonymous
Piper Sandler
HoldDowngrades$2.00+195.42%2022-03-31

1 of 1

Forecast return on equity

Is AKBA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is AKBA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

AKBA earnings per share forecast

What is AKBA's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.33
Avg 2 year Forecast
-$0.14
Avg 3 year Forecast
-$0.32

AKBA revenue forecast

What is AKBA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$203.6M-30.43%
Avg 2 year Forecast
$219.8M-24.9%
Avg 3 year Forecast
$75.1M-74.34%
AKBA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AKBA revenue growth forecast

How is AKBA forecast to perform vs Biotechnology companies and vs the US market?
Company
-29.64%
Industry
40.95%
Market
8.76%
AKBA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AKBA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AKBA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AKBA$0.68$1.63+140.03%Hold
ANVS$15.25$38.50+152.46%Strong Buy
CDTX$1.77$5.75+224.86%Strong Buy
LMNL$4.09$1.06-74.08%Sell
OCS$7.75N/AN/A
View Top Biotech Stocks

Akebia Therapeutics Stock Forecast FAQ

Is Akebia Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AKBA) stock is to Hold AKBA stock.

Out of 3 analysts, 0 (0%) are recommending AKBA as a Strong Buy, 0 (0%) are recommending AKBA as a Buy, 3 (100%) are recommending AKBA as a Hold, 0 (0%) are recommending AKBA as a Sell, and 0 (0%) are recommending AKBA as a Strong Sell.

If you're new to stock investing, here's how to buy Akebia Therapeutics stock.

What is AKBA's earnings growth forecast for 2023-2025?

(NASDAQ: AKBA) Akebia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Akebia Therapeutics's earnings in 2023 is -$92,562,000.On average, 2 Wall Street analysts forecast AKBA's earnings for 2023 to be -$60,801,855, with the lowest AKBA earnings forecast at -$62,644,335, and the highest AKBA earnings forecast at -$57,116,894. On average, 2 Wall Street analysts forecast AKBA's earnings for 2024 to be -$25,794,726, with the lowest AKBA earnings forecast at -$38,692,089, and the highest AKBA earnings forecast at -$14,739,844.

In 2025, AKBA is forecast to generate -$58,959,374 in earnings, with the lowest earnings forecast at -$132,658,592 and the highest earnings forecast at $16,582,324.

What is AKBA's revenue growth forecast for 2023-2025?

(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of -29.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Akebia Therapeutics's revenue in 2023 is $292,602,000.On average, 2 Wall Street analysts forecast AKBA's revenue for 2023 to be $37,505,532,040, with the lowest AKBA revenue forecast at $36,260,015,256, and the highest AKBA revenue forecast at $38,751,048,824. On average, 2 Wall Street analysts forecast AKBA's revenue for 2024 to be $40,488,507,889, with the lowest AKBA revenue forecast at $40,062,894,905, and the highest AKBA revenue forecast at $40,914,120,873.

In 2025, AKBA is forecast to generate $13,835,185,699 in revenue, with the lowest revenue forecast at $11,815,827,126 and the highest revenue forecast at $15,854,544,272.

What is AKBA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: AKBA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is AKBA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $1.63, with the highest AKBA stock price forecast at $2.00 and the lowest AKBA stock price forecast at $1.25.

On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $1.63 by Mar 10, 2024. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 140.03% from the current AKBA share price of $0.68.

What is AKBA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: AKBA) Akebia Therapeutics's current Earnings Per Share (EPS) is -$0.51. On average, analysts forecast that AKBA's EPS will be -$0.33 for 2023, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.31. On average, analysts forecast that AKBA's EPS will be -$0.14 for 2024, with the lowest EPS forecast at -$0.21, and the highest EPS forecast at -$0.08. In 2025, AKBA's EPS is forecast to hit -$0.32 (min: -$0.72, max: $0.09).

What is AKBA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: AKBA) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.